DiaMedica preclinical data

In a mouse model of Type I diabetes, twice-daily DM-99 significantly reduced fasting plasma glucose (FPG) by 68% compared with untreated control mice at day 21 (p=0.05). The undisclosed naturally occurring protein that inhibits glycogen synthase kinase 3 beta (GSK3B) also non-significantly reduced total glucose. Final data, including insulin production and beta cell proliferation, are expected in summer 2010. ...